Table 1 Patient demographics and baseline characteristics (full analysis set)
| Â | Placebo (NÂ =Â 70) | Canagliflozin 100Â mg (NÂ =Â 76) |
|---|---|---|
Sex, N (%) | ||
 Male | 49 (70.0) | 44 (57.9) |
 Female | 21 (30.0) | 32 (42.1) |
Age (years) | ||
 Mean ± SD | 56.1 ± 10.9 | 59.7 ± 9.4 |
Duration of diabetes (years) | ||
 Mean ± SD | 12.34 ± 8.21 | 15.18 ± 8.61 |
Body weight (kg) | ||
 Mean ± SD | 69.68 ± 13.13 | 69.95 ± 13.93 |
BMI (kg/m2) | ||
 Mean ± SD | 25.99 ± 4.40 | 26.88 ± 4.82 |
Waist circumference (cm) | ||
 Mean ± SD | 90.80 ± 10.97 | 92.93 ± 11.87 |
Diabetic complications, N (%) | ||
 All | 48 (68.6) | 50 (65.8) |
 Retinopathy | 26 (37.1) | 35 (46.1) |
 Neuropathy | 13 (18.6) | 14 (18.4) |
 Nephropathy | 28 (40.0) | 31 (40.8) |
Nondiabetic complications, N (%) | ||
 Hypertension | 40 (57.1) | 48 (63.2) |
 Dyslipidemia | 49 (70.0) | 63 (82.9) |
HbA1c (%) | ||
 Mean ± SD | 8.85 ± 0.84 | 8.89 ± 0.81 |
Fasting plasma glucose (mg/dL) | ||
 Mean ± SD | 169.1 ± 52.6 | 169.9 ± 44.4 |
Fasting C-peptide (ng/mL) | ||
 Mean ± SD | 1.018 ± 0.776 | 0.959 ± 0.703 |
HOMA2-Â %B (%) | ||
 Mean ± SD | 24.18 ± 13.84 | 22.62 ± 11.24 |
eGFR (mL/min/1.73Â m2) | ||
 Mean ± SD | 86.1 ± 21.7 | 83.8 ± 18.4 |
Daily dose of insulin (unit) | ||
 Mean ± SD | 28.1 ± 14.0 | 31.1 ± 15.1 |
Daily dose of insulin by insulin regimen (unit) | ||
 Premixed | ||
  N | 26 | 28 |
  Mean ± SD | 29.0 ± 11.6 | 33.1 ± 14.7 |
 Intermediate-acting | ||
  N | 0 | 0 |
  Mean ± SD | – | – |
 Long-acting | ||
  N | 24 | 24 |
  Mean ± SD | 20.9 ± 12.2 | 20.5 ± 12.3 |
 Premixed + rapid-or short-acting | ||
  N | 1 | 0 |
  Mean ± SD | 16.0 | – |
Intermediate + rapid-or short-acting | ||
  N | 0 | 0 |
  Mean ± SD | – | – |
 Long-acting + rapid-or short-acting | ||
  N | 19 | 24 |
  Mean ± SD | 36.7 ± 14.9 | 39.5 ± 12.1 |